GW Pharmaceuticals Plc, a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.
The move shows how the Cambridge, England-based company is emerging as a coveted target for larger pharmaceutical companies thanks to its key drug, Epidolex, which uses cannabis-based compounds to treat epilepsy.
GW has hired investment bank Morgan Stanley to help handle the overtures, the people said this week. The company is not currently interested in exploring a sale, and there is no certainty that any deal will occur, the people added.
The identity of the potential suitors could not be established. The sources asked not to be identified because the deliberations are confidential.
GW declined to comment. Morgan Stanley did not respond to a request for comment.
GW shares ended trading in London up 0.6 percent at 526.50 pence (70 U.S. cents), giving the company a market capitalization of 1.6 billion pounds ($2.1 billion). American depositary receipts of the company jumped as much as 22 percent in New York following the Reuters report.
GW’s move is the latest sign that dealmaking in the biotechnology sector is picking up. Last month, Pfizer Inc clinched a $14 billion acquisition of U.S. cancer drug company Medivation Inc.
Major players in the market for central nervous system treatments, including Allergan Plc and Biogen Inc , are searching for deals to build out their commercial presence and research and development pipelines.
Logical buyers for GW would include the companies that have partnered with it to distribute its marketed drug, Sativex, a nasal spray for multiple sclerosis that is also based on marijuana, one of the people said.
GW’s current partners include Novartis AG, Bayer AG and Almirall SA, among others.
Epidolex is in late-stage clinical trials and could receive approval from the U.S. Food and Drug Administration as soon as next year. It could eventually produce annual sales in excess of $800 million, according analysts at investment bank Cowen & Co.
The drug’s success is especially important to GW because of the tepid performance of Sativex, which has been marketed since 2010.
Sativex was never approved in the United States, and only produced $2 million in sales in the latest financial quarter.
GW Pharma is also exploring early-stage treatments for other illnesses, including diabetes and schizophrenia.
By Carl O’Donnell and Arno Schuetze
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.